Taken together, our ChaC1-based drug screening strategy delineates a synthetic lethal effect between AUR and proteasome inhibitor, proposing a clinically applicable strategy for repurposing these FDA-approved agents in HCC therapy. This evidence concerns the gene CHAC1 and hepatocellular carcinoma.